B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade therapy, according to a study at MD Anderson Cancer Center. Study results will be presented April 2 at the AACR Annual Meeting 2019 in Atlanta.
State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say researchers at Yale's School of Public Health and School of Medicine. Their study was published in the American Journal of Public Health.
New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy.
Array BioPharma Inc. the National Comprehensive Cancer Network has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include Braftovi in combination with Mektovi and an anti-EGFR antibody as a Category IIa treatment for patients with BRAFV600E-mutant metastatic colorectal cancer, after failure of one or two prior lines of therapy for metastatic disease.
TESARO announced the presentation of data from the phase I/II GARNET study evaluating dostarlimab in women with recurrent or advanced endometrial cancer who progressed on or after a platinum-based regimen.
A study led by University of Arkansas for Medical Sciences surgeon Brendan Stack has shown the potential to alter neck dissection surgeries in about 21 percent of head and neck cancer patients.
Genentech announced the submission of a supplemental New Drug Application to FDA for Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions.
A paper published in the Journal of the National Cancer Institute suggests that artificial intelligence systems may be able to perform as accurately as radiologists in the evaluation of digital mammography in breast cancer screening.
Myriad Genetics Inc. said the phase III POLO study demonstrated its BRACAnalysis CDx test successfully identified patients with metastatic pancreatic cancer who have BRCA mutations and benefitted from treatment with olaparib, a novel PARP inhibitor.
A study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy, according to a study led by researchers at the Johns Hopkins Kimmel Cancer Center.
